|
|
||||||||
1 School of Biological and Chemical Sciences, Birkbeck College, University of London, London, UK
2 School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington LE12 5RD, UK
3 School of Pharmacy, University of London, London, UK
Correspondence
Naveed Ahmed Khan
Naveed.Khan{at}nottingham.ac.uk
Received September 10, 2008
Accepted October 7, 2008
Acanthamoeba is an opportunistic protozoan pathogen that can cause blinding keratitis and a rare but fatal encephalitis involving the central nervous system with a very poor prognosis. This is due to limited availability of effective anti-acanthamoebic drugs. Here, we tested whether the use of liposomes can improve the potency of pentamidine isethionate, an anti-amoebic compound. The liposomes consisted of L-
-phosphatidylcholine and cholesterol or ergosterol in a molar ratio of 1 : 5. Pentamidine isethionate was incorporated to achieve a final drug to lipid ratio of 1 : 5. At a drug concentration of 10 µg ml–1, the liposomal drug was >12 times more effective than the free drug at preventing Acanthamoeba binding to human cells and significantly more effective in reducing parasite-mediated human cell cytopathogenicity, compared with the drug alone. Both the free and liposomal drug blocked Acanthamoeba encystation.
Abbreviations: HBMECs, human brain microvascular endothelial cells.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |